N/A
N=356
Time to DMARD (Disease-Modifying Anti-Rheumatic Drug) Treatment and Actual Work Limitation of Patients With Rheumatoid Arthritis in Turkey
Rheumatoid Arthritis
Bottom Line
View on ClinicalTrials.gov: NCT01144598 ↗Enrolled (actual)
356
Serious AEs
0.0%
Results posted
Sep 2012
Primary outcome: Primary: Evaluation of Disease Duration: Time From Diagnosis to Disease-Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis — 11.7177 Months
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Abbott
- Primary completion
- Aug 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Evaluation of Disease Duration: Time From Diagnosis to Disease-Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis |
11.7177 | — |
| SECONDARY Work Limitation: Health Assessment Questionnaire-Disability Index (HAQ-DI) |
0.96 | — |
| SECONDARY Work Limitation: Work Productivity and Activity Impairment (WPAI) Questionnaire |
12.3; 39.1; 42.3; 38.7 | — |
| SECONDARY Evaluation of Global Rheumatoid Arthritis Severity Scale |
4.07 | — |
| SECONDARY Evaluation of Disease Activity Score 28 (DAS28) |
84; 64; 129; 76 | — |
| SECONDARY Evaluation of Visual Analog Scale (VAS) for Pain and Fatigue |
4.24 | — |
| SECONDARY Number of Disease Modifying Anti-Rheumatic Drugs |
44; 94; 78; 35 | — |
| SECONDARY Biologics Usage |
85; 16; 4 | — |
| SECONDARY Stiffness Duration |
161; 78; 54; 62 | — |
| SECONDARY Number of Comorbidities |
259; 72; 22; 3 | — |
| SECONDARY Rheumatoid Factor |
248; 96 | — |
| SECONDARY Anti-cyclic Citrullinated Peptide |
181; 75 | — |
| SECONDARY Sedimentation Rate |
27.53 | — |
| SECONDARY Number of Deformities at Inspection |
221; 34; 33; 66 | — |
| SECONDARY Evaluation of Rheumatoid Arthritis Treatments Duration |
16.2468; 68.57 | — |
Summary
The objective is to measure time delay from onset of symptoms to diagnosis and time to disease-modifying anti-rheumatic drug treatments in Turkish patients with rheumatoid arthritis. The investigators will also evaluate actual work limitation status of patients and impact of demographic and clinical factors on work limitations in rheumatoid arthritis patients.
Eligibility Criteria
Inclusion Criteria
- Diagnosed with rheumatoid arthritis by a specialist or by the treating rheumatologist
- Treated with at least one disease-modifying anti-rheumatic drug or biologics
- Patients over 18 years
- Patients already employed at a paid work
- Patients able to provide data for disease history
- Able to provide written consent to release information for this study
Exclusion Criteria
- Patients who cannot provide necessary outcome measurements for any reason will be excluded from the study
Data sourced from ClinicalTrials.gov (NCT01144598). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.